Related Experiment Video
Updated: Apr 3, 2026

10:22
Enrichment of Bruch's Membrane from Human Donor Eyes
Published on: November 15, 2015
12.7K
Selective accumulation of the complement membrane attack complex in aging choriocapillaris.
Kathleen R Chirco1, Budd A Tucker1, Edwin M Stone1
1The Stephen A. Wynn Institute for Vision Research and the Department of Ophthalmology and Visual Sciences, The University of Iowa, Iowa City, IA, USA.
Experimental Eye Research
|September 15, 2015
Summary
The complement membrane attack complex (MAC) is primarily found in the eye's choriocapillaris, not other aging tissues. This restricted MAC accumulation may explain why age-related macular degeneration (AMD) affects the eye specifically.
Area of Science:
- Ophthalmology
- Immunology
- Pathology
Background:
- The complement membrane attack complex (MAC) is elevated in the choriocapillaris during aging and age-related macular degeneration (AMD).
- Perivascular MAC accumulation in the choroid is known, but its presence in other aging tissues is unclear.
Purpose of the Study:
- To investigate the abundance and localization of MAC across various human tissues.
- To determine if MAC deposition is unique to the ocular tissues affected by AMD.
Main Methods:
- Immunohistochemical labeling of paraffin-embedded human donor eyes (n=6) and a 19-tissue array.
- Antibodies used: anti-MAC, anti-intercellular adhesion molecule-1 (ICAM-1), and Ulex europaeus agglutinin-I (UEA-I).
- Confirmation using unfixed frozen sections of RPE-choroid and extraocular tissues.
Main Results:
- High MAC levels were exclusively detected in the choriocapillaris.
- MAC was not found in 38 additional samples from 19 diverse human tissues.
- ICAM-1 was widespread, and UEA-I labeled vasculature in all tissues examined.
Conclusions:
- MAC accumulation is highly restricted to the choriocapillaris.
- This ocular specificity of MAC may contribute to the targeted pathology of AMD in the retina, RPE, and choroid.
- The limited systemic distribution of MAC suggests a reason for the relative absence of systemic disease in AMD.

